5 results
hematology diagnosis syndrome algorithm anemia anticoagulation aplastic cancer cyp3a4 differentiation inducers inhibitors interactions malignancy pglycoprotein sjogrens table vte
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓) of cytochrome p450 CYP3A4 and P-glycoprotein. DOACs are substrates
(DOAC interactions ... ) Cancer-treatment ... inducers #inhibitors #Chemotherapy ... #Oncology #Hematology ... Interactions #Table #Pharmacology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis. Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... anticoagulants (DOACs ... thrombosis; PE = pulmonary ... Anticoagulation #Management ... #Hematology #Oncology
►
 Differentiation Syndrome in APML Epidemiology: • Incidence: common in APL (2-48% depending on the study) • Triggers:
Differentiation Syndrome in APML ... Triggers: ATRA treatment ... Imaging: CXR- pulmonary ... #diagnosis #management ... #hematology #oncology
Aplastic Anemia - Overview Who? • M = F • 3 peaks: 1) Childhood 2) 15-25 years 3) >60 years What? • Aplastic anemia
Cytotoxic drugs/Chemotherapy ... index < 2 • EPO Level ... aplastic anemia Treatment ... Aplastic #Anemia #oncology ... #management
Sjogren's Syndrome Overview Epidemiology: • F > M: 9:1 • 5-6th Decades (can be any age) Autoimmune exocrinopathy multisystemic disease
, INC risk PE, Pulmonary ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
No results found for "Lever treatment management pulmonary rheumatology pharmacology oncology doac chemotherapy apml"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #Lever #treatment #management #pulmonary #rheumatology #pharmacology #oncology #doac #chemotherapy #apml